DiscGenics welcomes you to NASS 2022!
DiscGenics is a privately held, clinical stage biopharmaceutical company developing an allogeneic, injectable cell therapy (IDCT) for symptomatic, mild to moderate lumbar disc degeneration. In an FDA-allowed, prospective, randomized, double-blinded, controlled, multicenter clinical study, high dose IDCT produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection. Improvements were sustained at the 52- and 78-week interim readouts with additional data to follow at 104 weeks.